Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32338708    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32338708  :  Publisher
PDF vom PMID32338708

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 #MMPMID32338708
  • Bhimraj A; Morgan RL; Shumaker AH; Lavergne V; Baden L; Cheng VC; Edwards KM; Gandhi R; Muller WJ; O'Horo JC; Shoham S; Murad MH; Mustafa RA; Sultan S; Falck-Ytter Y
  • Clin Infect Dis 2020[Apr]; ä (ä): ä PMID32338708show ga
  • BACKGROUND: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. OBJECTIVE: Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19. METHODS: IDSA formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. RESULTS: The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. CONCLUSIONS: The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.
  • ä

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    ä ä.ä 2020